北卡罗来纳州引入9价人乳头瘤病毒疫苗后第一年内接种的决定因素
本研究采用回顾性队列设计,利用北卡罗来纳州免疫登记处数据,纳入2015年7月至2016年10月期间9至17岁青少年接种的所有HPV疫苗剂次,分析接种9价HPV疫苗(9vHPV)而非其他HPV疫苗的个体和地区层面决定因素。结果显示,居住于年龄合格人口更多、健康专业人员短缺或人均年门诊就诊次数更高的地区者更可能接种9vHPV;年龄较大、接种公共资助剂次或居住于教育水平较低、宗教组织较多地区者更不可能接种9vHPV。结论认为虽过渡较快,但9vHPV推广存在差异。
要点
- 居住于年龄合格人口更多的地区者更可能接种9vHPV。
- 居住于健康专业人员短缺地区或人均年门诊就诊次数更高的地区者更可能接种9vHPV。
- 年龄较大、接种公共资助剂次或居住于教育水平较低、宗教组织较多地区者更不可能接种9vHPV。
核心结论
- 从其他HPV疫苗向9vHPV的过渡相对较快,但北卡罗来纳州9vHPV的推广存在差异。
研究设计与样本
- 回顾性队列设计,使用北卡罗来纳州免疫登记处(NCIR)数据,样本包括2015年7月至2016年10月期间接种的所有HPV疫苗剂次,对象为9至17岁年龄合格青少年。
主要发现
- 居住于年龄合格(9-17岁)人口更多的ZCTA者更可能接种9vHPV。
- 居住于健康专业人员短缺地区或人均年门诊就诊次数更高的ZCTA者更可能接种9vHPV。
- 年龄较大、接种公共资助剂次或居住于高中以下教育程度人口比例更高或宗教组织数量更多的ZCTA者更不可能接种9vHPV。
关键数值与推荐
- 使用逻辑回归模型分析个体儿童层面和ZCTA层面特征与接种9vHPV(对比其他HPV疫苗)指示变量的关联。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of this study was to describe the transition from bi- and quadrivalent HPV vaccines to 9vHPV in aggregate and identify determinants of the receipt of 9vHPV among youth following the introduction of 9vHPV in North Carolina. METHODS: The study used a retrospective cohort design with data from the North Carolina Immunization Registry (NCIR). Our sample included all doses of HPV vaccine administered between July 2015 and October 2016 to age-eligible youth (ages 9-17). We used a logistic regression model to associate individual child-level and ZIP Code Tabulation Area (ZCTA)-level characteristics with an indicator variable for receiving 9vHPV (vs. other HPV vaccines). RESULTS: Youth receiving the HPV vaccine were more likely to receive 9vHPV if they lived in a ZCTA with a larger age-eligible (i.e., 9-17) population, a health professional shortage area, or a higher number of annual outpatient visits per capita. They were less likely to receive 9vHPV if they were older, received a publicly-funded dose, or lived in a ZCTA with a higher percentage of the population with less than a high-school education or a higher number of religious organizations. CONCLUSIONS: While the transition from other HPV vaccines to 9vHPV was relatively quick, there were disparities in the diffusion of 9vHPV across North Carolina.
引用
- Trogdon JG, Shafer P, Lindsay B, et al. Determinants of the receipt of the 9-valent human papillomavirus vaccine in the first year after introduction in North Carolina. Vaccine. 2018. PMID: 29366705. doi:10.1016/j.vaccine.2018.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。